PennyPerformers.com: "Penny Stocks that Perform" picks are: DPS, DYAX, LVLT, TEVA, UNDT

Jun 25, 2009 (M2 PRESSWIRE via COMTEX) -- UNDT | Quote | Chart | News | PowerRating -- Pennyperformers.com "Penny Stocks that Perform" picks are: Dr Pepper Snapple Group, Inc. (NYSE: DPS), Dyax Corp. (NASDAQ: DYAX), Level 3 Communications Inc (NASDAQ: LVLT), Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), Universal Detection Technology (OTCBB: UNDT)

Sign-up for our FREE Stock Alerts AND NEWSLETTER at www.pennyperformers.com

Jun 25, 2009 -- Dr Pepper Snapple Group, Inc. (NYSE: DPS | Quote | Chart | News | PowerRating) today announced it has signed a multi-year agreement with Jack in the Box Inc. (Nasdaq: JACK) and its franchisees that now includes availability of both Dr Pepper and Diet Dr Pepper to all Jack in the Box(R) restaurants nationwide.

In July, Diet Dr Pepper will be made available to all of the nearly 2,200 Jack in the Box in the U.S. with national availability expected by year end. Dr Pepper is already available in all Jack in the Box restaurants nationally and will continue to be available under terms of the agreement.

"We are very excited about this opportunity to expand our successful 22-year relationship with Jack in the Box and its franchisees," said Dave Rollins, General Manager and Sr. Vice President, Foodservice of Dr Pepper Snapple Group. "Dr Pepper and Diet Dr Pepper are two of the best selling beverages in America and are a perfect fit with the Jack in the Box strategy of increasing soft drink sales in their restaurants."

"Dr Pepper is a strong brand that performs well in our system," said Terri Graham, SVP, Chief Marketing Officer for Jack in the Box. "Jack in the Box has one of the most varied menus in the QSR segment, and with the addition of Diet Dr Pepper, we're pleased to be able to offer our guests even more beverage options."

Dr Pepper was created in Waco, Texas, in 1885 and is the oldest major soft drink brand in America. It continues to be one of the most popular soft drinks, with both Dr Pepper and Diet Dr Pepper among the top 10 carbonated soft drink brands in the U.S.

About Dr Pepper Snapple Group

Dr Pepper Snapple Group, Inc. (NYSE: DPS | Quote | Chart | News | PowerRating) is the leading producer of flavored beverages in North America and the Caribbean. Our success is fueled by more than 50 brands that are synonymous with refreshment, fun and flavor. We have 6 of the top 10 non-cola soft drinks, and 9 of our 12 "power brands" are No. 1 in their respective categories. In addition to our flagship Dr Pepper and Snapple brands, our portfolio includes Sunkist soda, 7UP, A&W, Canada Dry, Crush, Mott's, Squirt, Hawaiian Punch, Penafiel, Clamato, Schweppes, Venom Energy, Rose's and Mr & Mrs T mixers.

About Jack in the Box Inc.

Jack in the Box Inc. (NASDAQ: JACK), based in San Diego, is a restaurant company that operates and franchises Jack in the Box(R) restaurants, one of the nation's largest hamburger chains, with more than 2,180 restaurants in 18 states. Additionally, through a wholly owned subsidiary, the company operates and franchises Qdoba Mexican Grill(R), a leader in fast-casual dining, with more than 480 restaurants in 42 states and the District of Columbia. The company also operates a proprietary chain of 61 convenience stores called Quick Stuff(R), each built adjacent to a full-size Jack in the Box restaurant and including a major-brand fuel station. The company has announced plans to sell its Quick Stuff brand.

Jun 25, 2009 -- Dyax Corp. (NASDAQ: DYAX | Quote | Chart | News | PowerRating) today announced that it has agreed to sell 7,425,743 shares of its common stock at a price of $2.02 per share in an underwritten public offering with no warrants. The price per share is equal to the closing price of Dyax's common stock on June 24, 2009. Dyax expects the net proceeds from the sale of the shares to be approximately $14 million, after underwriting fees and estimated offering expenses. In addition, Dyax has granted the underwriter a 30-day option to purchase up to an additional 1,113,862 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about June 30, 2009, subject to the satisfaction of customary closing conditions.

Deutsche Bank Securities Inc. is the sole underwriter for the offering.

Dyax intends to use the net proceeds from the offering to fund the development and commercialization of DX-88, the Company's ongoing research and preclinical activities, and for general corporate purposes.

The offering was made pursuant to a shelf registration statement that has been filed with and declared effective by the Securities and Exchange Commission. Additional information and details with respect to the offering will be included in a prospectus supplement and related prospectus that will be filed with the Securities and Exchange Commission prior to closing. When available, the prospectus supplement and the related prospectus may be obtained from Deutsche Bank Securities Inc., Attn: Prospectus Department, 100 Plaza One, Jersey City, New Jersey 07311, telephone: (800) 503-4611 or e-mail at prospectusrequest@list.db.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Dyax

Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. Dyax's lead product candidate is DX-88 (ecallantide), a recombinant small protein that is currently being evaluated for its therapeutic potential in two separate indications. On June 1, 2009, Dyax submitted a response to the FDA's Complete Response letter regarding the review of Dyax's Biologics License Application (BLA) of DX-88 for the treatment of hereditary angioedema (HAE). The FDA accepted the submission and assigned Dyax's BLA a new Prescription Drug User Fee Act (PDUFA) action date of December 1, 2009. DX-88 has orphan drug designation in the U.S. and E.U., as well as Fast Track designation in the U.S., for this indication. Additionally, DX-88 is being evaluated in Phase 2 trials for the prevention of blood loss during on-pump cardiothoracic surgery (CTS), which are being conducted by Dyax's partner, Cubist Pharmaceuticals. Dyax licensed to Cubist the intravenous formulation of DX-88 for surgical indications in North America and Europe. DX-88 and other compounds in Dyax's pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Dyax is headquartered in Cambridge, Massachusetts.

Jun 25, 2009 -- Level 3 Communications Inc (NASDAQ: LVLT | Quote | Chart | News | PowerRating) has completed deployment of a low-latency, fibre-optic network connection between New York and Chicago, the provider of fibre-based communications services said on Wednesday.

According to the company, the network expansion was deployed using the shortest-path routes and advanced electronics to enable high-speed transaction rates with low transmission delays, which is a significant service level requirement for financial exchanges and other trading venues.

The new route offers aggregate bandwidth of multiple 40Gb/s connections to accommodate growing traffic volume generated by hedge funds, investment brokers, financial exchanges and other market participants. Currently, over 80Gb/s of live financial trading traffic is being carried over the new route.

The company has also collaborated with financial services customers to design custom, low-latency network services to select trading venues throughout North America and Europe. Level 3 offers direct connections to 15 financial exchanges, 15 electronic communications networks and seven market data centres.

June 25, 2009 -- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA | Quote | Chart | News | PowerRating) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced completion of patient enrollment for the second pivotal Phase III clinical trial, BRAVO, evaluating the novel, oral once-daily immunomodulating compound, laquinimod, for the treatment of relapsing-remitting multiple sclerosis (RRMS). BRAVO is a global clinical trial designed to evaluate the efficacy, safety and tolerability of laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex(R).

The BRAVO study completed patient enrollment in June, recruiting more than 1,200 patients at 156 sites in the United States, Europe, Israel and South Africa.

"Teva and Active Biotech are encouraged by the potential of laquinimod to address patients' unmet need for an oral immunomodulating MS therapy that provides efficacy while maintaining safety" said Moshe Manor, Teva's Group Vice President, Global Branded Products. "We look forward to continuing our clinical Phase III program of laquinimod, and hope it will offer enhanced quality of health for RRMS patients".

ALLEGRO, the first global Phase III trial of laquinimod, completed enrollment in November 2008, after recruiting more than 1,000 patients at 152 sites in North America, Europe and Asia. The trial is currently ongoing.

In February 2009, laquinimod received Fast Track designation from the U.S. Food and Drug Administration (FDA).

About Multiple Sclerosis

Multiple sclerosis (MS) is the leading cause of neurological disability in young adults. It is estimated that more than 400,000 people in the United States are affected by the disease and that over two million people may be affected worldwide. MS is a progressive, demyelinating disease of the central nervous system affecting the brain, spinal cord and optic nerves. Demyelination is the destructive breakdown of the fatty tissue that protects nerve endings.

About Laquinimod

Laquinimod is a novel once-daily, orally administered immunomodulatory compound that is being developed as a disease-modifying treatment for RRMS. Active Biotech developed laquinimod and licensed it to Teva Pharmaceutical Industries, Ltd. in June 2004. A Phase IIb study in 306 patients was published in The Lancet (June 2008) and demonstrated that an oral 0.6 mg dose of laquinimod, administered daily, significantly reduced MRI disease activity by a median of 60 percent (51 percent mean reduction) versus placebo in RRMS patients. In addition, the study showed a favorable trend toward reducing annual relapse rates and the number of relapse-free patients compared with placebo. Treatment was well tolerated, with only some transient and dose-dependent increases in liver enzymes reported.

In addition to the efficacy that laquinimod has shown in Phase II RRMS clinical trials, laquinimod has demonstrated potent therapeutic efficacy in preclinical models of other autoimmune diseases such as rheumatoid arthritis, insulin-dependent diabetes mellitus, Guillain Barre Syndrome, lupus and Inflammatory Bowel Disease. The broad profile of efficacy in animal models of inflammatory diseases suggests that laquinimod affects a pivotal pathway of inflammation and autoimmunity. Laquinimod is currently in Phase II development for Crohn's disease and Teva expects to initiate the clinical development of the compound for Lupus Nephritis in the near future.

About the Phase III Program

ALLEGRO (assessment of oral laquinimod in preventing progression of MS) is a pivotal, global, 24/30-month, double-blind, Phase III study designed to evaluate the efficacy, safety and tolerability of laquinimod versus placebo in the treatment of RRMS.

BRAVO (benefit-risk assessment of Avonex(R) and laquinimod) is a pivotal, multinational, multi-center, randomized, double-blind, parallel-group, placebo-controlled study designed to compare the safety and efficacy of laquinimod with placebo and to provide risk-benefit data for laquinimod versus a currently available injectable treatment.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.

About Active Biotech

Active Biotech AB (NASDAQ OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA.

Jun 24, 2009 -- Universal Detection Technology (OTCBB: UNDT), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider of counter-terrorism consulting and training services, reported today that it has been awarded a North Atlantic Treaty Organization (NATO) CAGE Number for its biological weapon detection systems. The CAGE code allows for marketing of the instruments to NATO affiliated countries.

The NATO Commercial and Government Entity, or NCAGE, code is a five-character ID number that identifies government contractors. NCAGE codes are an important part for companies winning contracts with NATO affiliated countries. The UDT CAGE/NCAGE code is: 1WLU0. UNDT is now listed along with all U.S. and NATO companies with a CAGE/NCAGE Code. The code lists UNDT in a primary vendor database for the U.S. Federal Government and is used as a government tool for the Department of Homeland Security, Department of Defense, NATO and NASA Agencies. Having this information immediately available allows the U.S. Government and NATO countries to rapidly find the companies with the right capabilities to offer services for required government initiatives, including research & development projects, particular supply needs, up to a pandemic alert requirement or other emergency requirements.

"The awarding of our NCAGE code is a significant step for us to market our equipment to a rapidly expanding NATO alliance that has significant biological weapon detection needs," said Mr. Jacques Tizabi, UNDT's Chief Executive Officer.

About Universal Detection

Technology Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The Company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, the Company, in cooperation with NASA, has developed a bacterial spore detector that detects certain biohazard substances. The Company is also a reseller of handheld assays used for detection of five bioterrorism agents, radiation detection systems, and antimicrobial products.

About PennyPerformers.com

PennyPerformers.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

Penny Performers email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Penny Performers Report home page at www.PennyPerformers.com and select the "join now" button.

Join us at www.PennyPerformers.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. PennyPerformers.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyPerformers.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. PennyPerformers.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), PennyPerformers.com is owned and operated by PennyPerformers.com. Neither PennyPerformers.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since PennyPerformers.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in PennyPerformers.com statements and opinions and such statements and opinions cannot be considered independent. PennyPerformers.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. PennyPerformers.com services are often paid for using free-trading shares. PennyPerformers.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.PennyPerformers.com/disclaimer.htm

For More Information Regarding Penny Performers, Contact Jason A. Hilton: Rochester, Ny 14609 Office: (866)704-0122 Email: Jason@Newmediaadvisorsllc.com

CONTACT: Jason A. Hilton, New Media Advisors LLC Tel: +1 866 704 0122 e-mail: Jason@Newmediaadvisorsllc.com PennyPerformers.com e-mail: info@pennyperformers.com WWW: http://www.PennyPerformers.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index